Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04657965
Other study ID # LMP1-001
Secondary ID
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date January 15, 2021
Est. completion date January 15, 2027

Study information

Verified date December 2020
Source Zhejiang University
Contact He Huang, PhD
Phone 86-13605714822
Email hehuangyu@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A study of LMP1 CAR-T for patients with LMP1 positive infectious diseases and hematological malignancies


Description:

This is a single arm, open-label, single-center study. This study is indicated for LMP1 positive infectious diseases and hematological malignancies. The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 144 patients will be enrolled. Primary objective is to explore the safety, main consideration is dose-related safety.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 144
Est. completion date January 15, 2027
Est. primary completion date January 15, 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: Only applicable to the inclusion criteria of CAEBV 1. Subjects who are diagnosed with CAEBV according to the Okano revised standard proposed by the Japanese Ministry of Health, Labour and Welfare Research Group for the Prevention of Refractory Diseases; 2. All CAEBV patients who have not achieved complete remission, including: 1. Active phase: EBV-DNA level in PBMC is higher than 1×10^2.5 copies/µg DNA, with symptoms and signs of active diseases such as fever, hepatomegaly, splenomegaly, abnormal liver function, decrease of blood three lines, lymphadenopathy, and progressive skin lesions with increased EBV titer in peripheral blood; 2. inactive phase: EBV-DNA level in PBMC is higher than 1×10^2.5 copies/µg DNA, without symptoms and signs of active diseases; 3. The disease has not yet progressed to hematopoietic lymphohistiocytosis (HLH); Only applicable to the inclusion criteria of LMP1-positive ENKTL: 1. According to the 2016 WHO classification criteria for lymphocytic tumors: Subjects diagnosed by histopathology as extranodal NK/T cell lymphoma, nasal type (ENKTL) with LMP1 positive in tumor tissue; 2. R/R ENKTL (meets one of the following prerequisites) 1. Without remission or with progression after receiving second-line or higher-line chemotherapy/chemotherapy + radiotherapy; 2. Primary drug resistance; 3. With recurrence after receiving autologous/allogeneic hematopoietic stem cell transplantation; 3. According to 2014 Lugano standard, there should be at least one evaluable tumor lesion. Only applicable to the inclusion criteria for LMP1-positive HL: 1. According to the 2016 WHO classification criteria for lymphocytic tumors, subjects with Hodgkin lymphoma diagnosed by histopathology (HD) and LMP1 positive in tumor tissue; 2. R/R HD (meets one of the following prerequisites): 1. Without remission or with progression after receiving second-line or higher-line chemotherapy; 2. Primary resistance Drugs; 3. With recurrence after receiving autologous hematopoietic stem cell transplantation; 3. According to the Lugano 2014 standard, there should be at least one evaluable tumor lesion; Only applicable to the inclusion criteria for LMP1-positive PTLD: 1. Only PTLD after hematopoietic stem cell transplantation; 2. According to the 2016 WHO classification criteria for lymphocytic tumors, subjects with PTLD diagnosed by histopathology and LMP1 positive in tumor tissue; 3. Excluding PTLD of early-stage 4. R/R PTLD (meets one of the following prerequisites): 1. Without remission or with progression after receiving rituximab-based standard treatment; 2. Primary drug resistance; 5. According to the Lugano 2014 standard, there should be at least one evaluable tumor lesion Exclusion Criteria: Subjects with any of the following exclusion criteria were not eligible for this trial: 1. History of craniocerebral trauma, conscious disturbance,epilepsy,cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases; 2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past; 3. Pregnant (or lactating) women; 4. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis); 5. Active infection of hepatitis B virus or hepatitis C virus; 6. Concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving in haled steroids; 7. Previously treated with any CAR-T cell product or other genetically modified T cell therapies; 8. Creatinine>2.5mg/dl, or ALT / AST > 3 times of normal amounts, or bilirubin>2.0 mg/dl; 9. Other uncontrolled diseases that were not suitable for this trial; 10. Patients with HIV infection; 11. Any situations that the investigator believes may increase the risk ofpatients or interfere with the results of study

Study Design


Intervention

Drug:
LMP1 CAR T-cells
Each subject receive LMP1 CAR T-cells by intravenous infusion

Locations

Country Name City State
China The First Affiliated Hospital,College of Medicine, Zhejiang University Hangzhou Zhejiang

Sponsors (2)

Lead Sponsor Collaborator
Zhejiang University Yake Biotechnology Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity (DLT) Adverse events assessed according to NCI-CTCAE v5.0 criteria Baseline up to 28 days after LMP1 targeted CAR T-cells infusion
Primary Incidence of treatment-emergent adverse events (TEAEs) Incidence of treatment-emergent adverse events [Safety and Tolerability] Up to 2 years after LMP1 targeted CAR T-cells infusion
Secondary Chronic active EB virus infection (CAEBV), Overall response rate (ORR) Assessment of ORR (ORR = CR + PR) at Month 1, 3, 6, 12, 18 and 24 At Month 1, 3, 6, 12, 18 and 24
Secondary CAEBV,Duration of remission(DOR) From the first remission after LMP1 CAR-T cells to relapse, death or the last visit Up to 2 years after LMP1 CAR-T cells infusion
Secondary CAEBV, Overall survival (OS) From the first infusion of LMP1 CAR-T cells to death or the last visit Up to 2 years after LMP1 CAR-T cells infusion
Secondary CAEBV, Relapse rate(RR) From the first remission after LMP1 CAR-T cells to relapse or the last visit At Month 6, 12, 18 and 24
Secondary CAEBV, Event-free survival (EFS) From the first infusion of LMP1 CAR-T cells to the occurrence of any event, including death, relapse or gene relapse, disease progression (any one occurs first), and the last visit Up to 2 years after LMP1 CAR-T cells infusion
Secondary Hodgkin's lymphoma(HL), Extranodal NK/T cell lymphoma(ENKTL),Nasal type, Lymphoproliferative disease after hematopoietic stem cell transplantation, (post-HSCT PTLD),Overall response rate (ORR) Assessment of ORR (ORR = CR + PR) at Month 1, 3, 6, 12, 18 and 24 At Month 1, 3, 6, 12, 18 and 24
Secondary HL, ENKTL, PTLD, OS From the first infusion of LMP1 CAR-T cells to death or the last visit Up to 2 years after LMP1 CAR-T cells infusion
Secondary HL, ENKTL, PTLD, EFS From the first infusion of LMP1 CAR-T cells to the occurrence of any event, including death, relapse or gene relapse, disease progression (any one occurs first), and the last visit Up to 2 years after LMP3 CAR-T cells infusion
Secondary Quality of life Assessment using European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) scale [For item1-28: max score: 112, min score: 28, higher scores mean a better outcome; for item 28-29: max score: 14, min score: 2, higher scores mean a worse outcome] to measure Quality of life at Baseline, Month 1, 3, 6, 9 and 12 At Baseline, Month 1, 3, 6, 9 and 12
Secondary Activities of Daily Living (ADL) score Assessment using Activities of Daily Living (ADL) scale (Barthel Index) [max score: 100, min score: 0, higher scores mean a better outcome] at Baseline, Month 1, 3, 6, 9 and 12 At Baseline, Month 1, 3, 6, 9 and 12
Secondary Instrumental Activities of Daily Living (IADL) score Assessment of Instrumental Activities of Daily Living (IADL) scale [max score: 56, min score: 14, higher scores mean a worse outcome] at Baseline, Month 1, 3, 6, 9 and 12 At Baseline, Month 1, 3, 6, 9 and 12
Secondary Hospital Anxiety and Depression Scale (HADS) score Assessment using Hospital Anxiety and Depression Scale (HADS) [max score: 42, min score: 0, higher scores mean a worse outcome] at Baseline, Month 1, 3, 6, 9 and 12 At Baseline, Month 1, 3, 6, 9 and 12
See also
  Status Clinical Trial Phase
Terminated NCT03248479 - Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies Phase 1
Recruiting NCT05454241 - CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies Phase 2
Recruiting NCT06041815 - Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies
Active, not recruiting NCT05005442 - A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) Phase 2
Recruiting NCT02300571 - Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant N/A
Active, not recruiting NCT01428973 - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens Phase 2
Completed NCT00379587 - Rituximab for Prevention of Chronic GVHD Phase 1/Phase 2
Completed NCT01162096 - Reduced Intensity Haploidentical Transplant for Hematological Malignancies Phase 1/Phase 2
Terminated NCT00506948 - Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD) Phase 2
Active, not recruiting NCT04557098 - A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Phase 2
Recruiting NCT04283097 - Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects Phase 1
Completed NCT03067155 - CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation. Phase 2
Completed NCT01725555 - A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors Phase 1
Completed NCT00438178 - Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies Phase 1
Completed NCT03711604 - Compassionate Use Study of Tenalisib (RP6530) Phase 1/Phase 2
Withdrawn NCT01168882 - Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies Phase 1
Completed NCT01246206 - Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT Phase 2
Completed NCT01172132 - The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH" N/A
Completed NCT00506402 - A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies Phase 1
Active, not recruiting NCT00163644 - RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT N/A